ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase ( ALK )-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Published 2017 View Full Article

Authors

Keywords

Anaplastic lymphoma kinase, NSCLC, Ceritinib, Food-effect study

Journal

Journal of Thoracic Oncology

Volume 12, Issue 9, Pages 1357-1367

Publisher

Elsevier BV

Online

2017-07-18

DOI

10.1016/j.jtho.2017.07.005

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now